Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(50%)
Results Posted
67%(2 trials)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_2
5
50%
Ph phase_4
3
30%
Ph phase_3
1
10%

Phase Distribution

0

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
3(30.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(3)
Terminated(1)

Detailed Status

Recruiting4
Completed3
Not yet recruiting1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (50.0%)
Phase 31 (10.0%)
Phase 43 (30.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting110%
recruiting440%
withdrawn110%
completed330%
active_not_recruiting110%

Recent Activity

5 active trials
Showing 5 of 10
active_not_recruitingphase_2

Effects of Semaglutide in HIV-Associated Lipohypertrophy

NCT04019197
recruitingnot_applicable

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

NCT04174755
recruitingphase_4

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

NCT06706284
recruitingphase_4

Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

NCT07136714
completedphase_2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

NCT06500429
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04019197Phase 2

Effects of Semaglutide in HIV-Associated Lipohypertrophy

Active Not Recruiting
NCT04174755Not Applicable

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Recruiting
NCT06706284Phase 4

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Recruiting
NCT07136714Phase 4

Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

Recruiting
NCT06500429Phase 2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

Completed
NCT05895643Phase 2

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Completed
NCT05786521Phase 4

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Completed
NCT06423599Phase 2

Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure

Recruiting
NCT05646199Phase 2

Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

Not Yet Recruiting
NCT04885634Phase 3

Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10